Cytomegalovirus end-organ disease in immunocompromised critically ill patients: key concerns demanding attention

Abstract

We delved into the clinical research conducted by Sara Fernández et al. [1] with great interest. This study is a multicenter, international research initiative spanning over a decade, primarily focusing on cytomegalovirus end-organ disease (CMV-EOD) among immunosuppressed patients with critical illness. The study revealed distinctive clinical features, risk factors, and adverse clinical outcomes in immunocompromised critically ill patients with CMV-EOD, marking it as a seminal work in the field. However, there is scope for enhancing the comprehensiveness of this study with further refinements.

First, within the specific population of immunocompromised critically ill patients, certain subjects (such as those with sepsis, trauma, and other prolonged illnesses) have been overlooked and excluded. Sepsis, a significant global health concern characterized by severe response to infection that causes organ failure, leads to over 5.3 million deaths yearly, with a mortality rate of around 30% [2,3,4]. Sepsis is currently understood to induce an imbalance in the immune system (innate and adaptive), leading to phenomenon known as "immune paralysis" [5,6,7]. The early stages (characterized by overwhelming inflammation) and the later stages (characterized by refractory inflammation, immunosuppression, and risk of secondary infections) of sepsis are both conducive to CMV reactivation [5,6,7,8]. The incidence of CMV reactivation in septic patients seems to be similar to other common immunosuppressed patients [8]. Our team's research indicates the incidence of CMV reactivation in critically ill patients with concurrent sepsis increases by at least 30%, and sepsis is an independent risk factor for CMV reactivation [9, 10]. This aligns with other mainstream research findings, where the underlying mechanism is associated with sepsis-induced immunosuppression, promoting CMV replication [11]. Therefore, definition of immunosuppressed population in CMV-EOD research should be broadened, and more effective immune function assessment indicators are required to clearly define "immunocompromised", moving beyond reliance on clinical disease types for judgment.

Second, assessing the impact of CMV load levels on clinical characteristics and outcomes in CMV-EOD population is essential. Additionally, it is necessary to evaluate CMV seropositivity, both qualitatively and quantitatively, as recent studies indicate a close relationship between CMV seropositivity and poor prognosis [12]. A combined assessment of CMV load and IgG in blood may enable earlier identification of high-risk patients, allowing for antiviral treatment to improve adverse outcomes. Third, the antiviral medications used for the subjects with CMV-EOD in this study may exert a negative influence on prognosis, primarily due to bone marrow suppression leading to a decrease in immune cell levels [13]. The use of the latest anti-CMV drugs Letermovir and Maribavir may mitigate these adverse effects [14]. Finally, CMV should be recognized as a systemic infectious virus, not confined to a specific organ but widely infecting various cell types, including epithelial, endothelial, fibroblast cells, and so on [15]. Notably, CMV resides in the body as a latent infection and can reactivate under immunosuppressed conditions, leading to multi-system organ damage, particularly affecting the respiratory and digestive systems in patients with CMV-EOD. However, whether CMV is a pathogen or a bystander remains a significant and unresolved question. The prevailing view is that CMV reflects immune status and has pathogenicity, especially as reactivation is more likely with lower immune function, and the pathogenicity increases with viral load. In addition, the impact of other co-infections on prognosis needs to be clarified.

In conclusion, the study by Sara Fernández et al. describes the clinical characteristics and outcomes of immunocompromised critically ill patients with CMV-EOD, thus contributing positively to the advancement of the field. A nuanced investigation into the aforementioned matters is essential to fully elucidate the intricate interplay between CMV-EOD and poor prognosis in immunocompromised critically ill patients. Further research should delve deeper into these complexities to enhance our understanding and potentially inform more effective therapeutic strategies.

No datasets were generated or analysed during the current study.

CMV:

Cytomegalovirus

CMV-EOD:

Cytomegalovirus End-Organ Disease

1. Fernández S, Grafia I, Peyrony O, et al. Clinical characteristics and outcomes of immunocompromised critically ill patients with cytomegalovirus end-organ disease: a multicenter retrospective cohort study. Crit Care. 2024;28(1):243. https://doi.org/10.1186/s13054-024-05029-4.

   Article PubMed PubMed Central Google Scholar

2. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10. https://doi.org/10.1001/jama.2016.0287.

   Article PubMed PubMed Central Google Scholar

3. Liu V, Escobar GJ, Greene JD, et al. Hospital deaths in patients with sepsis from 2 independent cohorts. JAMA. 2014;312(1):90–2. https://doi.org/10.1001/jama.2014.5804.

   Article PubMed Google Scholar

4. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence. 2014;5(1):4–11. https://doi.org/10.4161/viru.27372.

   Article PubMed Google Scholar

5. Hotchkiss RS, Moldawer LL, Opal SM, et al. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045. https://doi.org/10.1038/nrdp.2016.45.

   Article PubMed PubMed Central Google Scholar

6. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862–74. https://doi.org/10.1038/nri3552.

   Article PubMed PubMed Central Google Scholar

7. Skirecki T, Drechsler S, Jeznach A, et al. An early myelosuppression in the acute mouse sepsis is partly outcome-dependent. Front Immunol. 2021;12:708670. https://doi.org/10.3389/fimmu.2021.708670.

   Article PubMed PubMed Central Google Scholar

8. Ong DSY, Chong GM, Chemaly RF, et al. Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression. Clin Microbiol Infect. 2022;28(10):1335–44. https://doi.org/10.1016/j.cmi.2022.05.034.

   Article PubMed Google Scholar

9. Zhang Z, Li R, Chen Y, et al. Association between active cytomegalovirus infection and lung fibroproliferation in adult patients with acute respiratory distress syndrome: a retrospective study. BMC Infect Dis. 2022;22(1):788. https://doi.org/10.1186/s12879-022-07747-y.

   Article PubMed PubMed Central Google Scholar

10. Zhang Z, Liu X, Sang L, et al. Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study. BMC Infect Dis. 2021;21(1):1026. https://doi.org/10.1186/s12879-021-06698-0.

    Article PubMed PubMed Central Google Scholar

11. Marandu T, Dombek M, Cook CH. Impact of cytomegalovirus load on host response to sepsis. Med Microbiol Immunol. 2019;208(3–4):295–303. https://doi.org/10.1007/s00430-019-00603-y.

    Article PubMed Google Scholar

12. Unterberg M, Ehrentraut SF, Bracht T, et al. Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis. Crit Care. 2023;27(1):417. https://doi.org/10.1186/s13054-023-04713-1.

    Article PubMed PubMed Central Google Scholar

13. Cowley NJ, Owen A, Shiels SC, et al. Safety and efficacy of antiviral therapy for prevention of cytomegalovirus reactivation in immunocompetent critically ill patients: a randomized clinical trial. JAMA Intern Med. 2017;177(6):774–83. https://doi.org/10.1001/jamainternmed.2017.0895.

    Article PubMed PubMed Central Google Scholar

14. Razonable RR. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients. Clin Microbiol Infect. 2023;29(9):1144–9. https://doi.org/10.1016/j.cmi.2023.03.020.

    Article PubMed Google Scholar

15. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759–73.

    Article PubMed PubMed Central Google Scholar

Download references

Not applicable.

The study was funded by the National Natural Science Foundation of China (No. 82070084), Science and Technology Program of Guangzhou (Nos. SL2023A04J00179, 2024A04J3312), and Guangzhou Clinical Specialty Program (No. 2023C-TS01).

Author notes

1. Yimin Li and Xiaoqing Liu have contributed equally to the study.

Authors and Affiliations

1. Department of Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China

   Zhihui Zhang, Junlu Sun, Xuesong Liu, Rong Zhang, Yimin Li & Xiaoqing Liu

Authors

1. Zhihui ZhangView author publications

   You can also search for this author in PubMed Google Scholar

2. Junlu SunView author publications

   You can also search for this author in PubMed Google Scholar

3. Xuesong LiuView author publications

   You can also search for this author in PubMed Google Scholar

4. Rong ZhangView author publications

   You can also search for this author in PubMed Google Scholar

5. Yimin LiView author publications

   You can also search for this author in PubMed Google Scholar

6. Xiaoqing LiuView author publications

   You can also search for this author in PubMed Google Scholar

Contributions

ZHZ wrote the manuscript; ZHZ, JLS, XSL, and RZ revised the manuscript; XQL and YML reviewed the manuscript. XQL and YML contributed equally to the study. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Yimin Li or Xiaoqing Liu.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Accordance statement

Not applicable.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

Cite this article

Zhang, Z., Sun, J., Liu, X. et al. Cytomegalovirus end-organ disease in immunocompromised critically ill patients: key concerns demanding attention. Crit Care 28, 298 (2024). https://doi.org/10.1186/s13054-024-05070-3

Download citation

• Received: 15 August 2024

• Accepted: 17 August 2024

• Published: 10 September 2024

• DOI: https://doi.org/10.1186/s13054-024-05070-3

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative